Citadel Advisors LLC lowered its position in Rezolute, Inc. (NASDAQ:RZLT) by 1.4% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 307,988 shares of the company’s stock after selling 4,348 shares during the period. Citadel Advisors LLC owned about 3.69% of Rezolute worth $4,395,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other large investors have also added to or reduced their stakes in RZLT. Millennium Management LLC purchased a new position in Rezolute in the first quarter worth $190,000. Vanguard Group Inc. purchased a new position in Rezolute in the second quarter worth $419,000. Finally, Northern Trust Corp purchased a new position in Rezolute in the second quarter worth $459,000. Hedge funds and other institutional investors own 25.66% of the company’s stock.
Several research analysts have weighed in on the stock. JMP Securities lowered their target price on shares of Rezolute from $30.00 to $18.00 and set a “buy” rating on the stock in a research report on Monday, November 15th. Zacks Investment Research downgraded Rezolute from a “hold” rating to a “sell” rating in a research report on Wednesday, November 17th. Roth Capital initiated coverage on Rezolute in a research report on Wednesday, September 8th. They set a “buy” rating and a $21.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $21.00 target price on shares of Rezolute in a research report on Friday, September 17th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus price target of $23.00.
Rezolute (NASDAQ:RZLT) last released its earnings results on Friday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.90) by ($0.02). Research analysts forecast that Rezolute, Inc. will post -4.1 earnings per share for the current year.
Rezolute, Inc operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. Its products portfolio include RZ358-Phase 2, an antibody for the ultra-orphan indication of congenital hyperInsulinism; AB101-Phase 1, a once-weekly injectable basal insulin; and RZ402 which targets diabetic macular edema.
Read More: What is the definition of arbitrage?
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.